Biotech Stocks To Follow Today - May 1st

Key Points

• MarketBeat highlights five Biotech stocks to watch today: MRNA (Moderna), DHR (Danaher), LABT (Lakewood‑Amedex Biotherapeutics), CELC (Celcuity), and VRTX (Vertex) — selected because they had the highest dollar trading volume among Biotech names in recent days.
• Biotech stocks carry high R&D and regulatory/clinical trial risk, producing volatile, often binary outcomes that can lead to substantial gains or steep losses depending on scientific and approval milestones.
• The list mixes large, marketed-therapy companies (e.g., Moderna with mRNA vaccines and Vertex with cystic fibrosis drugs) and smaller clinical-stage firms (Lakewood‑Amedex targeting antibiotic-resistant infections and Celcuity developing tumor-targeting diagnostics/therapies), offering different risk/reward profiles.

Moderna, Danaher, Lakewood-Amedex Biotherapeutics, Celcuity, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that use biological research and technologies to discover, develop, and commercialize drugs, therapies, diagnostics, and life‑science tools. For investors they tend to carry high R&D costs and regulatory/clinical trial risk, producing volatile, binary outcomes that can lead to either substantial gains or steep losses depending on scientific and approval milestones. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Read Our Latest Research Report on MRNA

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read Our Latest Research Report on DHR

Lakewood-Amedex Biotherapeutics (LABT)

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others.

Read Our Latest Research Report on LABT

Celcuity (CELC)

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

Read Our Latest Research Report on CELC

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read Our Latest Research Report on VRTX

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.